PROMISE Proteomics’ Post

A high-throughput, sensitive and reproduiable PTM enrichment workflow from Prof. Mann and others. They optimzed SDC-based lysis/digestion workflow for following antibody-based enrichment. With single LC-MS run on QE HF-X, more phosphorylated peptides or simliar number (but require less sample input) were identified and highly reproducible quantified. The most interesting is that, besides the number, this worklfow can even report more peptides from membrane protein or tranmembrane proteins, this will be a huge help for membrane proteomics~. 

𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐂𝐃𝐱 𝐞𝐁𝐨𝐨𝐤: Explore the next frontier in companion diagnostics and how next-gen #proteomics methods for protein biomarker discovery are opening exciting new avenues in CDx development. https://lnkd.in/gpPcr2vd 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐨 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫: ⚪️ The predictive value offered by dynamic protein biomarkers for CDx applications. ⚪️ How mass spectrometry-based proteomics is expanding the CDx landscape with deeper coverage of the plasma & tissue proteome. ⚪️ Approaches to rapidly translate protein biomarkers for clinical impact. https://lnkd.in/gpPcr2vd

𝐂𝐃68 (𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲) 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰: The CD68 antibody market is growing due to its crucial role in immune system research and diagnostic applications. CD68 antibodies are primarily used in the identification of macrophages in immunohistochemistry and flow cytometry. Their applications in cancer research, inflammatory diseases, and other immune-related disorders are driving market expansion. The increasing research and development activities, along with advancements in personalized medicine, are further boosting the demand for CD68 antibodies in various clinical and research applications. 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨 @ https://lnkd.in/gTcNJAr3 𝐓𝐨𝐩 45 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: American Baseball Coaches Association (ABCA), Thermo Fisher Scientific, Bio-Rad Laboratories, Sigma-Aldrich, Cell Signaling Technology (CST), Santa Cruz Biotechnology (SCBT), R&D Systems, BD BIOSCIENCES PHARMINGEN, PerkinElmer, MilliporeSigma, Thermo Fisher Scientific, Merck Group, Vector Laboratories, Inc., Atlas Antibodies, BioGenex, LSBio | LifeSpan BioSciences, Inc., Epitomics Inc, New England Biolabs, Cayman Chemical, Enzo Life Sciences, Inc., DAKO GmbH, Bio-Techne, LonzaBoster Biological Technology, GenScript, Chondrex, Inc, #CD68Antibody #ImmunologyResearch #CancerResearch #InflammatoryDiseases #AntibodyMarket

Nutritionally physiological cell culture medium and 3D culture influence breast tumour proteomics and anti-cancer drug effectiveness: https://lnkd.in/esDaK8QV  #BreastCancer #Proteomics #Proteomics #PharmacolRes #openaccess #Research 

🩸How can you make the most of MS-based proteomics for large cohorts of clinical blood samples? Check out this webinar to learn how to confidently prepare plasma with ENRICH-iST technology in a streamlined workflow for plasma profiling and biomarker discovery, featuring experts from Preomics and the University of Oxford. Now available on demand: https://ow.ly/FsNG50T21q7 #proteomics #plasmaprep #sampleprepration#LCMS #MassSpec #clinicalresearch #webinar

Exciting study from Genentech & Jena University Hospital! Susan Klaeger, Denys Oliinyk and others have unveiled their work using a dia-PASEF workflow on the timsTOF SCP for HLA-I peptide identification and quantification. Key Takeaways: The dia-PASEF workflow identified 11,412 unique peptides from 12.5 million cells and 3,426 8-11mers from as low as 500,000 cells with high reproducibility. By leveraging in-silico predicted spectral libraries and SILAC-DIA, the study achieved high quantitative accuracy, enhancing the detection of tumor-specific epitopes and neoantigens. #Proteomics #MassSpec #timsTOFSCP #CancerResearch #Genentech #HLAPeptides #diaPASEF

2025 starts with a new publication of my doctoral thesis!! :) "The use of a penta-deuterophenyl substituent to improve the metabolic stability of a tirosine kinase inhibitor" I hope you enjoy the reading! https://lnkd.in/d-fu_ipf #medicinalchemistry #pancreaticcancer #organicsynthesis #deuteriumatoms

Protein conformations with limited proteolysis coupled to mass spectrometry Significant improvements in limited proteolysis coupled to mass spectrometry (LiP-MS) protocols, including advanced digestion and data acquisition methods, have expanded its capabilities for structural proteomics. LiP-MS has been used in diverse experimental models, including mammalian cells, microbial, fungal, and plant systems, and also biofluids, offering new insights into protein function and interactions. LiP-MS can be used to investigate disease mechanisms, offering insights into protein dynamics in conditions such as cancer and neurodegenerative diseases. Recent studies leverage LiP-MS for drug–target interaction profiling to aid the discovery and development of novel therapeutics. LiP-MS is expected to advance structural proteomics and (bio)medical research, thereby aiding biomarker discovery and therapeutic target identification. #sciencenewshighlights #ScienceMission https://lnkd.in/gWuVH3e3 https://lnkd.in/gxUpH5Cd

#ASCOGI25 This is an intriguing study (Ibrahim Y. Abdelgawad, PhD.). According to the results, increased exposure to Temab‑A correlates significantly with a higher probability of molecular response, while c‑Met protein expression levels (H‑Score) and MET amplification status have no impact on the exposure of either the Temab‑A conjugate or its payload. This finding indicates that the pharmacokinetics of Temab‑A are independent of these biomarkers. This outcome raises a key question: which factors influence Temab‑A exposure? ABBV‑400 employs a bromoacetamide–Val‑Ala cleavable linker to enhance antibody–linker stability compared to traditional maleimide‑based linkers, thereby improving plasma stability. AbbVie likely incorporated this linker into ABBV‑400 to overcome the limitation of Teliso‑V, which demonstrated efficacy only in tumors with high c‑Met expression. The primary goal was to develop a drug that could function effectively regardless of c‑Met expression levels. The PK data from this study appear to support this design rationale. Using the bromoacetamide–Val–Ala cleavable linker, the drug likely achieves increased plasma stability and remains intact until it reaches the tumor microenvironment, where the payload can be released efficiently.

This is a continuation of the #protein - #peptide work I did on the intrinsic apoptotic pathway back at the Bioinformatics Institute, A*STAR in #Singapore and The University of Manchester. Here, I extend the analysis from native #BH3 peptide - Bcl-XL/Bcl-2 interactions to small molecule emulators. I'm sure this will be very interesting and of good use to anyone working in the #bcl and #apoptosis space. This is highly relevant to #cancer therapy with several new drugs (e.g. #venetoclax or #sonrotoclax) approved or in clinical trials for certain types of #lymphoma or #leukemia. Moreover, from a purely theoretical perspective, it makes a worthwhile contribution to the subject of #specificity and #affinity in #protein - #ligand interactions in #drugdesign. Pdf available upon request.